Search results for "HEPATITIS B"

showing 10 items of 451 documents

The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into funct…

2000

Abstract Objective . Hyper-IL-6, a fusion protein of interleukin-6 and its specific receptor, together with stem cell factor leads to the proliferation of primitive hematopoietic progenitor cells. Based on these findings, the current study examined whether hyper-IL-6 promotes the growth of precursor cells that can be further differentiated into dendritic cells in the presence of additional cytokines. Methods . Dendritic cell cultures were generated from CD34 + hematopoietic progenitor cells derived either from bone marrow or from peripheral blood. CD34 + cells were cultured in the presence of cytokines for 2 weeks and then used for phenotyping and T-cell stimulation assays. Results . Hyper-…

CD4-Positive T-LymphocytesCancer ResearchRecombinant Fusion ProteinsAntigen presentationBiologyDinoprostoneImmunophenotypingAntigens CDOxytocicsGeneticsCytokine Receptor gp130HumansProgenitor cellAntigen-presenting cellMolecular BiologyCells CulturedInterleukin 3Antigen PresentationStem Cell FactorMembrane GlycoproteinsFollicular dendritic cellsInterleukin-6Tumor Necrosis Factor-alphaGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationCell BiologyHematologyDendritic cellDendritic CellsReceptors InterleukinFlow CytometryHematopoietic Stem CellsHepatitis B Core AntigensReceptors Interleukin-6Recombinant ProteinsCell biologyEndothelial stem cellMyeloid-derived Suppressor CellInterleukin-4Cell DivisionInterleukin-1Experimental hematology
researchProduct

Clonal analysis of human T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis

1988

Human T lymphocytes infiltrating the liver in chronic active hepatitis B (CAH-B) and primary biliary cirrhosis were isolated from liver biopsy cores, cloned by limiting dilution technique and expanded in vitro. Phenotypic and functional analysis demonstrates that this tissue infiltrate represents a heterogeneous cell population. However, when compared to peripheral blood lymphocytes of the same patients, a marked enrichment for T8+ cytotoxic T cells was found to exist at a local site in both types of chronic liver disease. These data provide support for the notion that liver cell injury in CAH-B and PBC may be mediated by a common immunologic mechanism likely executed by cells of the T line…

CD4-Positive T-LymphocytesCytotoxicity ImmunologicPathologymedicine.medical_specialtyT-LymphocytesBiliary cirrhosisImmunologyChronic liver diseasePrimary biliary cirrhosismedicineHumansImmunology and AllergyCytotoxic T cellHepatitis Chronicmedicine.diagnostic_testLiver Cirrhosis Biliarybusiness.industryLiver cellHepatobiliary diseaseAntibodies MonoclonalT lymphocyteHepatitis Bmedicine.diseaseClone CellsKiller Cells NaturalLiver biopsyImmunologybusinessT-Lymphocytes CytotoxicEuropean Journal of Immunology
researchProduct

Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mut…

1995

To assess the significance of cell-mediated immunity, T cells were derived from the peripheral blood and liver tissue of hepatitis B virus (HBV)-infected patients and controls. The analysis of the 3H-thymidine-uptake in response to a panel of recombinant HBV antigens revealed that peripheral blood mononuclear cells (PBMC) of the 25 viremic patients with inflammatory active, chronic hepatitis B, 16 with wild-type and nine with HBe-minus HBV mutant infection, showed stronger proliferative responses to HBc and HBe antigens than 16 asymptomatic nonviremic HBsAg carriers with normal aminotransferase levels (HBc: SI 19.3 +/- 3.9 vs. 13.0 +/- 3.2 vs. 8.0 +/- 1.2; P.01 and HBe: SI 16.6 +/- 4.0 vs. …

CD4-Positive T-LymphocytesHBsAgHepatitis B virusmedicine.disease_causeVirusAntigenmedicineHumansHepatitis B e AntigensHepatitis B virusHepatologybiologybusiness.industryvirus diseasesInterferon-alphaHepatitis Bmedicine.diseasebiology.organism_classificationHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesHBcAgHBeAgHepadnaviridaeImmunologyChronic DiseaseMutationbusinessCell DivisionHepatology (Baltimore, Md.)
researchProduct

Molecular Basis for the Interaction of the Hepatitis B Virus Core Antigen with the Surface Immunoglobulin Receptor on Naive B Cells

2001

ABSTRACTThe nucleocapsid of the hepatitis B virus (HBV) is composed of 180 to 240 copies of the HBV core (HBc) protein. HBc antigen (HBcAg) capsids are extremely immunogenic and can activate naive B cells by cross-linking their surface receptors. The molecular basis for the interaction between HBcAg and naive B cells is not known. The functionality of this activation was evidenced in that low concentrations of HBcAg, but not the nonparticulate homologue HBV envelope antigen (HBeAg), could prime naive B cells to produce anti-HBc in vitro with splenocytes from HBcAg- and HBeAg-specific T-cell receptor transgenic mice. The frequency of these HBcAg-binding B cells was estimated by both hybridom…

CD4-Positive T-LymphocytesImmunologyNaive B cellAntigen presentationMolecular Sequence DataImmunoglobulin Variable RegionMice Transgenicmedicine.disease_causeAntibodies ViralMicrobiologyMiceAntigenVirologymedicineAnimalsHumansAmino Acid SequenceReceptors ImmunologicHepatitis B virusAntigen PresentationB-LymphocytesMice Inbred BALB Cbiologyvirus diseasesAntibodies MonoclonalVirologyMolecular biologyHepatitis B Core Antigensdigestive system diseasesPeptide FragmentsVirus-Cell InteractionsHBcAgHBeAgImmunoglobulin MImmunoglobulin MInsect Sciencebiology.proteinMice Inbred CBAImmunoglobulin Light ChainsBinding Sites AntibodyAntibodyImmunoglobulin Heavy ChainsSequence Alignment
researchProduct

Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the…

2011

Abstract Strategies for antibody-mediated cancer immunotherapy, such as active immunization with virus-like particle (VLP)-based vaccines, are gaining increasing attention. We developed chimeric hepatitis B virus core antigen (HBcAg)-VLPs that display a surface epitope of the highly selective tumor-associated cell lineage marker claudin-18 isoform 2 (CLDN18.2) flanked by a mobility-increasing linker. Auto-antibodies elicited by immunization with these chimeric HBcAg-VLPs in 2 relevant species (mouse and rabbit) bind with high precision to native CLDN18.2 at physiologic densities on the surface of living cells but not to the corresponding epitope of the CLDN18.1 splice variant that differs b…

Cancer ResearchHepatitis B virusLung Neoplasmsmedicine.medical_treatmentMolecular Sequence DataCHO CellsAdenocarcinomaActive immunizationCancer VaccinesEpitopeMiceCricetulusAntigenVirus-like particleCancer immunotherapyAntibody SpecificityStomach NeoplasmsCell Line TumorCricetinaemedicineAnimalsHumansProtein IsoformsAmino Acid SequenceVaccines Virus-Like ParticleAutoantibodiesMice Inbred BALB Cbiologybusiness.industryAntibody-Dependent Cell CytotoxicityMembrane ProteinsVirologyMolecular biologyHepatitis B Core AntigensHBcAgHEK293 CellsOncologyCell cultureClaudinsbiology.proteinRabbitsAntibodybusinessCancer research
researchProduct

Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study

2021

BACKGROUND There is an increased risk of atherosclerosis in patients with chronic hepatitis C or human immunodeficiency virus, but there is scarce data on hepatitis B virus infection. The hypothesis of this study is that hepatitis B virus infection increases the risk of carotid plaques and subclinical atherosclerosis in naïve hepatitis B e antigen (HBeAg) negative subjects. AIM To assess the rate of carotid plaques and subclinical atherosclerosis in naïve HBeAg negative subjects in comparison with a cohort of healthy controls. METHODS Prospective case-control collaborative study conducted in two tertiary hospitals. Four hundred and two subjects prospectively recruited at the outpatient clin…

Carotid Artery DiseasesHepatitis B virusmedicine.medical_specialtyIntima-media thicknessCardiovascular risk Carotid plaques Endothelial dysfunction Hepatitis B virus Intima-media thickness Subclinical atherosclerosis Carotid Intima-Media Thickness Hepatitis B e Antigens Humans Prospective Studies Carotid Artery Diseases Hepatitis B Chronicmedicine.disease_causeCarotid Intima-Media ThicknessGastroenterologyHepatitis B ChronicInternal medicinemedicineHumansOutpatient clinicCarotid plaquesSubclinical atherosclerosisEndothelial dysfunctionHepatitis B e AntigensProspective StudiesRisk factorProspective cohort studyHepatitis B virusbusiness.industryGastroenterologyGeneral MedicineOdds ratioHepatitis BCardiovascular riskmedicine.diseaseIntima-media thicknessHBeAgProspective StudybusinessWorld Journal of Gastroenterology
researchProduct

Inorganic Nanoparticle as a Carrier for Hepatitis B Viral Capsids

2011

Virus like particles (VLP) are used to transport immune response-modulating agents to target cells to treat them. In order to deliver a high concentration of VLP to the cell, a number of VLP can be attached to a nanoparticle to be used as a nanolorry. In this study, SiO2 nanoparticles were attached to Hepatitis B VLP. Spectrophotometry measurements, electron, and fluorescent microscopy evidence showed that the SiO2 – Hepatitis B VLP complexes were formed.

Chemistryvirusesvirus diseasesNanoparticleHepatitis Bmedicine.diseasecomplex mixturesVirologyVirusImmune systemCapsidSio2 nanoparticlesmedicineFluorescence microscopeHepatitis b viral
researchProduct

Microesferas de ácido poliláctico marcadas con 166Ho. Una alternativa frente a las de 90Y en el tratamiento del carcinoma hepático mediante radioembo…

2021

Los tumores hepáticos constituyen un importante problema de salud a nivel mundial que en multitud de ocasiones va asociado a patologías previas y factores de riesgo como las hepatitis víricas B y C, el consumo excesivo de alcohol y el aumento de casos de esteatohepatitis no alcohólica, cada vez más relevante en los países industrializados.En hepatocarcinomas no susceptibles de resección quirúrgica, la braquiterapia se está mostrando muy eficaz frente a la quimioterapia sistémica y transarterial, por lo que se desarrollan nuevos tratamientos locorregionales mínimamente invasivos y con menor toxicidad.La radioembolización hepática es una forma de braquiterapia consistente en la administración…

Chemotherapymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentBrachytherapyMagnetic resonance imagingViral hepatitis bmedicine.diseaseLower energyMicrospheremedicineHigh dosesSteatohepatitisbusinessNuclear medicineNereis. Interdisciplinary Ibero-American Journal of Methods, Modelling and Simulation.
researchProduct

Gender differences in chronic HBsAg carriers in Italy: Evidence for the independent role of male sex in severity of liver disease

2015

It has been shown that sexual hormones have an opposite effect on hepatic fibrosis progression and hepatocellular carcinoma development. Sex differences among 2,762 chronic HBsAg carriers consecutively referring Italian hospitals in 2001 and in 2007 have been evaluated, particularly focusing on the role of gender on severity of liver disease. The overall sex ratio (males/females) was 2.6. Females were more likely born abroad and new diagnosis cases; but less likely HIV coinfected. No sex difference was observed regarding coinfection with other hepatitis viruses. The sex ratio linearly increased with increasing severity of liver disease, being 1.3 in normal ALT, 2.8 in chronic hepatitis, 3.6…

Cirrhosisbusiness.industryHepatitis Bmedicine.diseaseVirologydigestive system diseasesVirusLiver diseaseInfectious DiseasesVirologyHepatocellular carcinomamedicineCoinfectionHepatic fibrosisbusinessSex ratioJournal of Medical Virology
researchProduct

Causes of and prevention strategies for hepatocellular carcinoma.

2012

Hepatocellular carcinoma (HCC) is a challenging malignancy of global importance. It is associated with a high rate of mortality and its prevalence in the United States and in Western Europe is increasing. Cirrhosis is the strongest and the most common known risk factor for HCC, usually due to hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. However, different lines of evidence identify in non-alcoholic fatty liver disease (NAFLD) a possible relevant risk factor for occurrence of HCC. Given the continuing increase in the prevalence of obesity and diabetes, the incidence of non-alcoholic steatohepatitis-related HCC may also be expected to increase, and a potential role of behav…

Counselingmedicine.medical_specialtyCirrhosisCarcinoma HepatocellularHepatitis C virusDiseasemedicine.disease_causeGastroenterologyChemopreventionInternal medicineMedicineHumansRisk factorHepatitis B virusbusiness.industryIncidence (epidemiology)Hepatocellular carcinoma primary prevention chemopreventionFatty liverLiver NeoplasmsVaccinationHematologymedicine.diseaseHepatitis BHepatitis Cdigestive system diseasesOncologyHepatocellular carcinomaControlled Clinical Trials as TopicInterferonsbusinessSeminars in oncology
researchProduct